Drug Profile
Research programme: selective androgen receptor inhibitors - Oncternal Therapeutics
Alternative Names: GTx-SARD; SARD - Oncternal Therapeutics; Selective androgen receptor degrader - Oncternal TherapeuticsLatest Information Update: 07 May 2021
Price :
$50
*
At a glance
- Originator University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.
- Class Antiandrogens; Small molecules
- Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 31 Dec 2020 Oncternal Therapeutics has patent protection for SARD ligands and methods of use thereof in USA, Australia, Japan, and Russia
- 28 Apr 2020 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 07 Jun 2019 GTx has merged with Oncternal Therapeutics to form Oncternal Therapeutics